Catalent Inc (CTLT) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CTLT - US1488061029 - Common Stock
63.48 USD
0 (0%)
63.5 USD
+0.02 (+0.03%)
We assign a fundamental rating of 3 out of 10 to CTLT. CTLT was compared to 190 industry peers in the Pharmaceuticals industry. CTLT may be in some trouble as it scores bad on both profitability and health. CTLT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
CTLT had positive earnings in the past year.
CTLT had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CTLT reported negative net income in multiple years.
Each year in the past 5 years CTLT had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -4.25%, CTLT is doing good in the industry, outperforming 78.01% of the companies in the same industry.
With a decent Return On Equity value of -11.66%, CTLT is doing good in the industry, outperforming 75.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROIC | N/A |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTLT has a Gross Margin (21.82%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of CTLT has declined.
The Profit Margin and Operating Margin are not available for CTLT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
2. Health
2.1 Basic Checks
CTLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTLT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CTLT has been increased compared to 5 years ago.
CTLT has a worse debt/assets ratio than last year.
2.2 Solvency
CTLT has an Altman-Z score of 1.62. This is a bad value and indicates that CTLT is not financially healthy and even has some risk of bankruptcy.
CTLT has a better Altman-Z score (1.62) than 64.92% of its industry peers.
The Debt to FCF ratio of CTLT is 49.84, which is on the high side as it means it would take CTLT, 49.84 years of fcf income to pay off all of its debts.
CTLT has a better Debt to FCF ratio (49.84) than 78.01% of its industry peers.
CTLT has a Debt/Equity ratio of 1.38. This is a high value indicating a heavy dependency on external financing.
CTLT has a worse Debt to Equity ratio (1.38) than 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Altman-Z | 1.62 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
CTLT has a Current Ratio of 2.51. This indicates that CTLT is financially healthy and has no problem in meeting its short term obligations.
CTLT's Current ratio of 2.51 is in line compared to the rest of the industry. CTLT outperforms 46.07% of its industry peers.
CTLT has a Quick Ratio of 1.93. This is a normal value and indicates that CTLT is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CTLT (1.93) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
The earnings per share for CTLT have decreased strongly by -61.40% in the last year.
CTLT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -33.48% yearly.
CTLT shows a small growth in Revenue. In the last year, the Revenue has grown by 4.71%.
Measured over the past years, CTLT shows a quite strong growth in Revenue. The Revenue has been growing by 11.71% on average per year.
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
3.2 Future
The Earnings Per Share is expected to grow by 73.38% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.44% on average over the next years.
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 288.55, the valuation of CTLT can be described as expensive.
Based on the Price/Earnings ratio, CTLT is valued a bit cheaper than the industry average as 78.01% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.19. CTLT is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 41.25 indicates a quite expensive valuation of CTLT.
Based on the Price/Forward Earnings ratio, CTLT is valued a bit cheaper than the industry average as 76.44% of the companies are valued more expensively.
CTLT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 |
4.2 Price Multiples
76.96% of the companies in the same industry are more expensive than CTLT, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CTLT is valued a bit cheaper than 78.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 116.39 | ||
| EV/EBITDA | 36.47 |
4.3 Compensation for Growth
CTLT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CTLT's earnings are expected to grow with 113.64% in the coming years.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y148.11%
EPS Next 3Y113.64%
5. Dividend
5.1 Amount
No dividends for CTLT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
63.48
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners92.2%
Inst Owner Change0%
Ins Owners0.48%
Ins Owner Change0%
Market Cap11.52B
Revenue(TTM)4.42B
Net Income(TTM)-413.00M
Analysts52.86
Price Target64.77 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-149.78%
Min EPS beat(2)-336.02%
Max EPS beat(2)36.46%
EPS beat(4)1
Avg EPS beat(4)-365.14%
Min EPS beat(4)-1032.86%
Max EPS beat(4)36.46%
EPS beat(8)2
Avg EPS beat(8)-208.81%
EPS beat(12)5
Avg EPS beat(12)-141.22%
EPS beat(16)9
Avg EPS beat(16)-103.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-5.19%
Max Revenue beat(2)4.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-6.04%
Max Revenue beat(4)4.16%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)-0.33%
Revenue beat(16)8
Avg Revenue beat(16)-0.03%
PT rev (1m)0.11%
PT rev (3m)4.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.12%
EPS NY rev (1m)4.18%
EPS NY rev (3m)-6.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 | ||
| P/S | 2.61 | ||
| P/FCF | 116.39 | ||
| P/OCF | 28.88 | ||
| P/B | 3.25 | ||
| P/tB | 31.57 | ||
| EV/EBITDA | 36.47 |
EPS(TTM)0.22
EY0.35%
EPS(NY)1.54
Fwd EY2.42%
FCF(TTM)0.55
FCFY0.86%
OCF(TTM)2.2
OCFY3.46%
SpS24.36
BVpS19.51
TBVpS2.01
PEG (NY)0.82
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% | ||
| FCFM | 2.24% |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Debt/EBITDA | 11.05 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 6.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 90.27% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 1.62 |
F-Score5
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)125.99%
Cap/Depr(5y)159.79%
Cap/Sales(3y)11.57%
Cap/Sales(5y)13.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
EBIT growth 1Y-166.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year196.68%
EBIT Next 3Y58.17%
EBIT Next 5Y41.23%
FCF growth 1Y121.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.85%
OCF growth 3Y-14.78%
OCF growth 5Y1.59%
Catalent Inc / CTLT FAQ
What is the ChartMill fundamental rating of Catalent Inc (CTLT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CTLT.
What is the valuation status of Catalent Inc (CTLT) stock?
ChartMill assigns a valuation rating of 4 / 10 to Catalent Inc (CTLT). This can be considered as Fairly Valued.
Can you provide the profitability details for Catalent Inc?
Catalent Inc (CTLT) has a profitability rating of 3 / 10.
Can you provide the PE and PB ratios for CTLT stock?
The Price/Earnings (PE) ratio for Catalent Inc (CTLT) is 288.55 and the Price/Book (PB) ratio is 3.25.
What is the expected EPS growth for Catalent Inc (CTLT) stock?
The Earnings per Share (EPS) of Catalent Inc (CTLT) is expected to grow by 350.55% in the next year.